Bellvitge launches REMMA program to accelerate rare disease diagnosis

A team of 46 researchers aims to reduce the six-year waiting period for adults with undiagnosed rare conditions.

Generic image of a biomedical research laboratory with scientific equipment.
IA

Generic image of a biomedical research laboratory with scientific equipment.

The Bellvitge Biomedical Research Institute (IDIBELL) has launched the REMMA research program in Tarragona and the metropolitan area to optimize coordination among professionals treating rare adult diseases.

The program involves 46 researchers from 23 groups, aiming to bridge the gap between specialized research and clinical practice. On average, patients with rare diseases wait six years for a diagnosis, a delay that often leads to severe anxiety and depression.

"We intend to find synergies to move faster and go further, ensuring our results directly benefit patients."

Antoni Riera · REMMA Program Coordinator
Covering a population of 2.1 million people in Tarragona and the southern metropolitan area, REMMA will focus on over 390 rare diseases. These include neurological, cardiovascular, and hereditary oncological conditions, utilizing advanced biomarkers to identify symptoms that often appear less clearly in adults than in children.